The news: Drugmakers with strong public recognition and widespread consumer awareness are most likely to be cited by popular LLMs when answering questions about pharma brands and prescription medications, according to a June 2026 analysis from 5W.

The firm analyzed more than 60 common patient and consumer prompts (e.g., “best company for diabetes drugs”) tracked in Q2 2026 across six pharma sub-categories: metabolic and GLP-1, oncology, immunology and inflammation, vaccines and antivirals, cardiovascular and specialty, and generics and biosimilars.

Each prompt was run five times per engine across ChatGPT, Claude, Perplexity, Gemini, and Google AI Overviews.

Digging into the details: Within each pharma sub-category, brand prominence, advertising exposure, and consumer adoption drive AI citations, per 5W.

For example, Eli Lilly and Novo Nordisk accounted for the largest share of citations in GLP-1 and weight loss prompts. Surging consumer interest in weight loss drugs fueled extensive media coverage and social media conversation, elevating the visibility of treatments such as Ozempic, Wegovy, and Zepbound and driving the companies' citation share.

Other drugmakers with strong AI citation share in their subcategory include:

• Pfizer, AstraZeneca, and Moderna (manufacturers of the most widely used COVID-19 vaccines) were among the best-known brands in the diversified/vaccines category.
• AbbVie, a perennial leader in TV ad spending, ranked for its immunology drugs.
• Merck led for oncology. Its blockbuster Keytruda was the world's best-selling drug until Lilly's tirzepatide recently overtook it.

Why it matters: Four in 10 consumers who use AI tools to look up information use it to research prescription and OTC drugs, such as side effects and treatment options for specific conditions, per EMARKETER’s January 2026 US Digital Health survey. Medications are the second-most-common health-related LLM search after general information on symptoms and conditions.

Consumers using AI to research medications are exposed to a wide range of drug information and pharma brands, potentially influencing downstream health decisions. Some 18% of consumers who have used AI for health information say they've adjusted their medication after interacting with a chatbot, per a March 2026 Rock Health report.

Implications for pharma companies: AI visibility is likely a secondary concern for now rather than a primary one, though its importance varies by drugmaker.

• A company developing cancer therapies, for example, is more likely to prioritize reaching oncologists with clinical trial data, efficacy results, and prescribing information than optimizing for LLM citations.
• By contrast, makers of weight loss drugs have stronger incentives to consider AI visibility given how frequently consumers research these medications online and ask their doctors about them.

Still, as more clinicians and patients use AI assistants to research treatments, visibility in AI-generated answers will become an important complement to traditional medical education and scientific communication. Brand relevance and authority will increasingly be shaped by a company's visibility in these AI-generated responses.

This content is part of EMARKETER’s subscription Briefings, where we pair daily updates with data and analysis from forecasts and research reports. Our Briefings prepare you to start your day informed, to provide critical insights in an important meeting, and to understand the context of what’s happening in your industry. Not a subscriber? Click here to get a demo of our full platform and coverage.